CLDX Celldex Therapeutics

Celldex Therapeutics to Present at Jefferies Healthcare Conference

Celldex Therapeutics to Present at Jefferies Healthcare Conference

HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7th at 9:00 am ET. A webcast of the presentation will be available on the "" page of the "" section of the Celldex website. A replay will be available for 90 days following the event.

About Celldex Therapeutics, Inc.

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit .

Company Contact

Sarah Cavanaugh

Senior Vice President, Corporate Affairs & Administration

(508) 864-8337

Patrick Till

Meru Advisors

(484) 788-8560



EN
02/06/2023

Underlying

CLDXCelldex Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celldex Therapeutics

 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Reports First Quarter 2025 Financial Results and Provides Corp...

Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update Strong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in JunePhase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under developmentPhase 2 EOE study enrollment complete; ongoing enrollment in Phase 2 PN and AD studiesCelldex’s first bispecific for inflammatory diseases, CDX-622, Phase 1 study ongoing HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc...

May 8, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in...

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease Phase 2 study fully enrolled; data expected in 2H 2025 HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting...

May 5, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics to Present at Upcoming Investor Conferences

Celldex Therapeutics to Present at Upcoming Investor Conferences HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "” page of the "" section of the . Replays will be available for 90 days following the event. About Celldex Ther...

March 4, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics Presents Positive Preclinical Data from Inflammat...

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin -- Phase 1 study in healthy volunteers ongoing - HAMPTON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem ce...

March 3, 2025 1 EN
 PRESS RELEASE
Free
CLDX Celldex Therape...

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phas...

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU -- 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 -- 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 - HAMPTON, N.J., March 01, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CL...

March 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch